Medication Treatments

Study Assesses Two-Year Outcomes of OUD Patients Following Sublocade Clinical Trials
In a study of OUD patients following their transition from two Phase 3 clinical trials of Sublocade, 44% of participants self-reported sustained illicit opioid-free weeks for the duration of the project.
NCAD Spotlight: Assessing Advancements in OUD Medications and Their Delivery
Marc Fishman, MD, of Maryland Treatment Centers and the Johns Hopkins University School of Medicine, discusses new formulations of medicines to treat OUD and delivery strategies during the COVID-19 pandemic.
Braeburn Seeks Final Approval on Injectable Buprenorphine
Braeburn has requested final approval from the U.S. Food and Drug Administration for Brixadi, an injectable form of buprenorphine with weekly and monthly formulations.
Synthetic Molecule Shows Promise for Treating Cocaine Addiction
In a study of mice, a synthetic molecule was found to reduce cocaine and methamphetamine consumption and cravings without the side effects typically associated with other interventions, according to research published Thursday in the journal Cell.
Safety Study Finds Comparable Profile for Injectable Buprenorphine
A long-term safety study of extended-release buprenorphine illustrates a safety profile comparable to that of the sublingual version of the drug.
Temple Researchers Receive NIDA Grant to Study Cocaine Addiction Treatment
Researchers at Temple University have received a $1.77 million grant from the National Institute on Drug Abuse to study the effects of a therapy for the treatment of cocaine use disorder, according to a media report.
1 in 5 Emergency Dept. Physicians Ready to Offer Buprenorphine
A Yale study of 400 clinicians found that just 21% of emergency department clinicians say they are prepared to prescribe buprenorphine for the treatment of opioid use disorder.
Elevate Spotlight: Best Practices in Opioid Addiction Treatment
With the far reach of the opioid epidemic and the high comorbidity of opioid addiction with other psychiatric disorders, the session will be relevant to all attendees, not just those in addiction medicine.
NCAD West: Prescription Opioid Misuse Drops, but Providers Need to Stay Vocal
During the opening plenary of NCAD West on Thursday, Colorado Consortium for Prescription Drug Abuse director Rober Valuck, PhD, RPh, FNAP, implored attendees to aggressively fight barriers to treatment, scrutinize their own work, and learn from their peers.
NCAD West: Focus on Function When Treating Chronic Pain
Las Vegas Recovery Center chief medical officer Mel Pohl, MD, DFASAM, shared risks of using opioids to treat chronic pain and offered non-medication alternatives to improve patients’ ability to function on Thursday at NCAD West.
Lofexidine Demonstrates Efficacy During Early Opioid Withdrawal
SAN DIEGO—The opioid withdrawal drug lofexidine demonstrated statistically significant efficacy across a half-dozen patient- and clinician-reported outcomes during the first 7 days after immediate opioid cessation, according to study presented at…
Back to Top